Complete Genomics, a struggling DNA sequencing company in Silicon Valley, said on Monday that it had agreed to be acquired for USD 117.6 million by BGI-Shenzhen, a Chinese company that operates the world’s largest sequencing operation. The deal will need antitrust clearance, because of two key players in the DNA sequencing business in a highly capital intensive and research intensive industry, as well as clearance from a national security review by the Committee on Foreign Investment in the United States. It also requires approval from certain governmental authorities in China.
Featured News
Prediction Markets Face a Defining Legal Test
Aug 11, 2026 by
CPI
A Court Just Decided Your AI Browser Isn’t a Hacker
Aug 11, 2026 by
CPI
Judge Refuses to Pause NCAA Eligibility Order Amid Antitrust Fight
Aug 11, 2026 by
CPI
US Opens Antitrust Review of Kone’s $34 Billion TK Elevator Acquisition
Aug 11, 2026 by
CPI
Paramount-Warner Deal Turns Into Test of State Antitrust Power
Aug 11, 2026 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Antitrust Compliance
Jul 20, 2026 by
CPI
Your Antitrust Compliance Program: A Strong Voice in Your Defense
Jul 20, 2026 by
Joe Murphy
Antitrust Compliance for the AI Pricing Era
Jul 20, 2026 by
Alejandra Uria & Andre Geverola
Race to Report: Antitrust Leniency in the Whistleblower Era
Jul 20, 2026 by
Brian R. Faerstein & Nicole H. Sprinzen
Antitrust-By-Design: Competition Compliance in Digital Markets
Jul 20, 2026 by
Marcos Drummond Malvar, Gabriela Costa Carvalho Forsman & Luciana Mendes